This product is currently not available for purchase.


Effects of Src-inhibitors on osteoclasts in vitro. Edition No. 1

  • ID: 1910772
  • December 2008
  • 80 Pages
  • VDM Publishing House
1 of 3

The human skeleton is continuously regenerated in
order to repair damages of the bone and to maintain
homeostasis. Disturbances in the process of
remodelling can give rise to common bone disorders
such as osteoporosis. In Osteoporosis the resorption
of bone exceeds the formation of new bone resulting
in loss of bone mass and fractures. Many people
suffer from osteoporosis and other bone diseases and
therefore it is important to search for effective
pharmaceutical compounds. The Src inhibitor
substances SI35, SI34, SI83, SI24, and S2 were
studied for their effects on osteoclasts and bone
remodelling in vitro. The aim was to investigate
their functions on osteoclastic bone resorption
activity and osteoclast differentiation from
precursors. Also the effects on viability and the
number of osteoclasts were examined. Src inhibitor
substance SI83 had the strongest inhibitory
activity – in the resorption assays with coculture-
derived osteoclasts as well as in the resorption
assays with rabbit osteoclasts. All of the tested
substances had an effect on the differentiation of
osteoclasts derived from mouse coculture.

Note: Product cover images may vary from those shown
2 of 3

Stefanie, Stummer.
Stefanie Stummer, DI (FH): Medical and Pharmaceutical
Biotechnology studies at the IMC-University of Applied Sciences,
Krems (Austria). Assistant and PhD-student, Department of
Pharmaceutical Technology and Biopharmaceutics, University of
Vienna (Austria).

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


If you have a more general question about our products please try our


Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Corporation
  • Merck & Co., Inc.